SOURCE: Cutting Edge Information

October 10, 2008 08:18 ET

According to Cutting Edge Information's Research, Combined Cancer Vaccines and Immunostimulants Revenue to Double by 2012

RESEARCH TRIANGLE PARK, NC--(Marketwire - October 10, 2008) - According to the latest oncology research published by Cutting Edge Information, revenue from cancer vaccines and immunostimulants will increase from $2.7 billion to $5.8 billion by 2012.

The report, "The Oncology Market Forecast to 2013" (http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp), examines major oncology indications, classes and more than 135 individual approved and investigational brands that will have the greatest impact in the next five years. In addition, the study analyzes the top-selling oncology brand manufacturers' current and future market presences.

According to the report, the overall oncology market is expected to surge to $90 billion by 2012, as every major pharmaceutical company seeks to restore revenue growth through promising oncology compounds. Within the therapeutic area, however, cancer vaccines and immunostimulants represent some of the most exciting research. Even as critics accuse drug manufacturers of chasing pipe dreams, these companies continue to invest billions of dollars in researching potential vaccines in-house, as well as scouring for available compounds to in-license.

While the general public is familiar with Gardasil -- the Merck blockbuster that claims to prevent cervical cancer causing viruses -- fewer have heard about Trovax and Provenge and countless investigational compounds that attempt to promote an active immune response that will conquer cancer. Though only one or two of these cancer vaccines could potentially reach market by 2012, several more will be progressing through clinical trials for approvals further into the decade.

With many promising compounds in development, the industry is only beginning to realize the potential for cancer vaccines and immunostimulants. Indeed, these are the cancer drugs of the future. The company that neglects to invest resources in cancer vaccine research will miss out on a high-growth segment of the oncology market.

Cutting Edge Information's 420+ page study examines 9 cancer vaccines and immunostimulants and more than 120 other drugs, and provides the following market analysis:

--  Individual Drug Profiles -- Drug profiles include information about
    drugs' competitive, strategic and market growth positions.
--  Oncology Indication Market Outlook -- Detailed outlooks for the
    breast, colorectal, lung and prostate cancer and leukemia markets.
--  Drug Manufacturer Profiles -- Oncology breakdowns for companies that
    either have established oncology franchises or exciting development
    pipelines for new cancer compounds.
    

Contact Information